Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways.

PURPOSE Results in a prior study have demonstrated that systemic administration of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin to healthy subjects reduces intraocular pressure and increases retinal blood flow. However, it remains unclear whether simvastatin can directly elicit dilation of retinal microvessels. In the current study, the direct effect and the underlying mechanism of the vasomotor action of simvastatin in retinal arterioles was studied. METHODS Porcine retinal arterioles ( approximately 75 mum internal diameter) were isolated, cannulated, and pressurized (55 cmH(2)O) without flow for in vitro study. Diameter changes in response to simvastatin were recorded using videomicroscopic techniques. RESULTS Retinal arterioles dilated dose dependently to simvastatin (1 nM to 10 muM). This vasodilation was significantly reduced after removal of the endothelium. The nitric oxide (NO) synthase inhibitor l-NAME (N(G)-nitro-l-arginine methyl ester) markedly inhibited the vasodilation, and combined administration of l-NAME with cyclooxygenase inhibitor indomethacin mimicked the effect of denudation. Blockade of soluble guanylyl cyclase by ODQ (1H-[1,2,4] oxadiazolo[4,3,-a]quinoxalin-1-one) produced a similar inhibitory effect as that by l-NAME. In contrast, the dilation was unaffected by cytochrome-P450 epoxygenase inhibitor sulfaphenazole. Intraluminal incubation of vessels with mevalonate, an immediate metabolite of HMG-CoA reductase, partially inhibited vasodilation to simvastatin. The Rho kinase inhibitor Y-27632 abolished the antagonistic effect of mevalonate. CONCLUSIONS Simvastatin elicits mainly an endothelium-dependent, NO-mediated dilation of retinal arterioles via activation of guanylyl cyclase; cyclooxygenase plays a relatively minor role. It appears that inhibition of the mevalonate-Rho kinase pathway in endothelial cells contributes in part to the simvastatin-induced vasodilation. A better understanding of the action of statins on retinal vasculature may help shed light on its therapeutic potential in retinal vascular disease.

[1]  A. Yeşilkaya,et al.  Peroxynitrite inactivates prostacyclin synthase by heme-thiolate-catalyzed tyrosine nitration. , 1999, Drug metabolism reviews.

[2]  R. Andriantsitohaina,et al.  Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat , 2000, British journal of pharmacology.

[3]  L. Kuo,et al.  Dilation of retinal arterioles in response to lactate: role of nitric oxide, guanylyl cyclase, and ATP-sensitive potassium channels. , 2006, Investigative ophthalmology & visual science.

[4]  M. Iida,et al.  EFFECTS OF FLUVASTATIN ON ENDOTHELIUM‐DERIVED HYPERPOLARIZING FACTOR‐ AND NITRIC OXIDE‐MEDIATED RELAXATIONS IN ARTERIES OF HYPERTENSIVE RATS , 2004, Clinical and experimental pharmacology & physiology.

[5]  M. Selley Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice , 2005, Brain Research.

[6]  佐藤 俊之 The mechanism of thrombin-induced prostacyclin synthesis in human endothelial cells with reference to the gene transcription of prostacyclin-related enzymes and Ca[2+] kinetics , 2000 .

[7]  R. Brandes,et al.  Lovastatin maintains nitric oxide--but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery. , 1999, Atherosclerosis.

[8]  今野 優 Retinal blood flow changes in type I diabetes : A long-term follow-up study , 1996 .

[9]  M. Brown,et al.  cDNA cloning of MEV, a mutant protein that facilitates cellular uptake of mevalonate, and identification of the point mutation responsible for its gain of function. , 1992, The Journal of biological chemistry.

[10]  L. Yannuzzi,et al.  The effects of lipid lowering on diabetic retinopathy. , 1991, American journal of ophthalmology.

[11]  S. Gupte,et al.  Hypoxia enhances a cGMP-independent nitric oxide relaxing mechanism in pulmonary arteries. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[12]  C. Sobey,et al.  Opposing Roles of Endothelial and Smooth Muscle Phosphatidylinositol 3-Kinase in Vasoconstriction: Effects of Rho-Kinase and Hypertension , 2005, Journal of Pharmacology and Experimental Therapeutics.

[13]  C. Owsley,et al.  Statins and other cholesterol-lowering medications and the presence of glaucoma. , 2004, Archives of ophthalmology.

[14]  T. Sawamura,et al.  Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina. , 2002, Archives of ophthalmology.

[15]  C. McCulloch,et al.  Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. , 2004, American journal of ophthalmology.

[16]  S. Chłopicki,et al.  Statins as coronary vasodilators in isolated bovine coronary arteries--involvement of PGI2 and NO. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[17]  M. Herrera,et al.  Cardiovascular effects of lovastatin in normotensive and spontaneously hypertensive rats. , 1998, General pharmacology.

[18]  T. Lüscher,et al.  Heterogeneity of endothelium-dependent regulation in ophthalmic and ciliary arteries. , 1993, Investigative ophthalmology & visual science.

[19]  D. Lefer,et al.  The effects of statins on endothelium, inflammation and cardioprotection. , 2005, Drug news & perspectives.

[20]  K. Kaibuchi,et al.  Rho GTPase/Rho Kinase Negatively Regulates Endothelial Nitric Oxide Synthase Phosphorylation through the Inhibition of Protein Kinase B/Akt in Human Endothelial Cells , 2002, Molecular and Cellular Biology.

[21]  T. Nurkiewicz,et al.  Calcium‐Independent Release of Endothelial Nitric Oxide in the Arteriolar Network: Onset During Rapid Juvenile Growth , 2004, Microcirculation.

[22]  L. Kuo,et al.  Effect of systemic administration of simvastatin on retinal circulation. , 2006, Archives of ophthalmology.

[23]  A. Pastuszyn,et al.  Cytochrome p-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. , 2003, American journal of physiology. Heart and circulatory physiology.

[24]  K. Franchini,et al.  Simvastatin Prevents Load-Induced Protein Tyrosine Nitration in Overloaded Hearts , 2004, Hypertension.

[25]  N. Delanty,et al.  Vascular effects of statins in stroke. , 1997, Stroke.

[26]  B. Tesfamariam The Effects of HMG-CoA Reductase Inhibitors on Endothelial Function , 2006, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[27]  M. Manzoni,et al.  Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs , 2002, Applied Microbiology and Biotechnology.

[28]  M. Herrera,et al.  Effect of simvastatin on vascular smooth muscle responsiveness: involvement of Ca(2+) homeostasis. , 2001, European journal of pharmacology.

[29]  R. Cohen,et al.  Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle , 1994, Nature.

[30]  R. Caldwell,et al.  Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. , 1999, Journal of the American College of Cardiology.

[31]  J. Liao,et al.  oxLDL specifically impairs endothelium-dependent, NO-mediated dilation of coronary arterioles. , 2000, American journal of physiology. Heart and circulatory physiology.

[32]  A. Mueck,et al.  Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells. , 2000, International journal of clinical pharmacology and therapeutics.

[33]  S. Watts,et al.  Inhibition of nitric oxide-induced vasodilation by gap junction inhibitors: a potential role for a cGMP-independent nitric oxide pathway. , 1996, Journal of vascular research.

[34]  M. Glucksberg,et al.  Direct measurement of retinal microvascular pressures in the live, anesthetized cat. , 1993, Microvascular research.

[35]  L. Kuo,et al.  Requisite roles of A2A receptors, nitric oxide, and KATP channels in retinal arteriolar dilation in response to adenosine. , 2005, Investigative ophthalmology & visual science.

[36]  C. Curcio,et al.  Complex mutations of USH2A gene denote ARRP , 2003, The British journal of ophthalmology.

[37]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[38]  J. Bertoglio,et al.  Modulation of COX-2 Expression by Statins in Human Aortic Smooth Muscle Cells , 2001, The Journal of Biological Chemistry.

[39]  F. Fyhrquist,et al.  Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. , 2004, American journal of physiology. Heart and circulatory physiology.

[40]  R. Busse,et al.  Endothelium-derived epoxyeicosatrienoic acids and vascular function. , 2006, Hypertension.

[41]  B. Vollrath,et al.  Effects of statins on vascular function of endothelin‐1 , 2005, British journal of pharmacology.

[42]  L. Schmetterer,et al.  Assessment of optic disk blood flow in patients with open-angle glaucoma. , 2000, American journal of ophthalmology.

[43]  M. Wolzt,et al.  Effect of pravastatin on responsiveness to N-monomethyl-L-arginine in patients with hypercholesterolaemia. , 2002, Atherosclerosis.

[44]  U. Laufs,et al.  Direct vascular effects of HMG-CoA reductase inhibitors. , 2000, Trends in cardiovascular medicine.

[45]  R. Andriantsitohaina,et al.  Simvastatin and Ca(2+) signaling in endothelial cells: involvement of rho protein. , 2001, Biochemical and biophysical research communications.

[46]  R. Gregg,et al.  Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. , 1999, Journal of cardiovascular pharmacology.

[47]  J. Falck,et al.  Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. , 1998, American journal of physiology. Renal physiology.

[48]  R. Gryglewski,et al.  Comparison of Endothelial Pleiotropic Actions of Angiotensin Converting Enzyme Inhibitors and Statins , 2001, Annals of the New York Academy of Sciences.

[49]  G. Barnes,et al.  A novel method to assess reactivities of retinal microcirculation. , 1994, Microvascular research.

[50]  U. Laufs,et al.  Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase* , 1998, The Journal of Biological Chemistry.

[51]  P. Neuvonen,et al.  Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors , 1998, Clinical pharmacology and therapeutics.

[52]  P. Neuvonen,et al.  Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations , 1998, Clinical pharmacology and therapeutics.

[53]  L. Kuo,et al.  cAMP-independent dilation of coronary arterioles to adenosine : role of nitric oxide, G proteins, and K(ATP) channels. , 1999, Circulation research.

[54]  L. Dobrucki,et al.  Increased Nitric Oxide Bioavailability in Endothelial Cells Contributes to the Pleiotropic Effect of Cerivastatin , 2002, Circulation.

[55]  G. Fried,et al.  Effects of nitric oxide donors and inhibitors of nitric oxide signalling on endothelin- and serotonin-induced contractions in human placental arteries. , 2002, Acta physiologica Scandinavica.

[56]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[57]  B. Kemp,et al.  Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. , 2004, American journal of physiology. Heart and circulatory physiology.

[58]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[59]  N. Youhnovski,et al.  Specific Nitration at Tyrosine 430 Revealed by High Resolution Mass Spectrometry as Basis for Redox Regulation of Bovine Prostacyclin Synthase* , 2003, The Journal of Biological Chemistry.

[60]  J. Vane,et al.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. , 1978, Pharmacological reviews.

[61]  R. Roman,et al.  Mechanism of cGMP contribution to the vasodilator response to NO in rat middle cerebral arteries. , 2002, American journal of physiology. Heart and circulatory physiology.

[62]  G. Ying,et al.  Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. , 2005, Investigative ophthalmology & visual science.

[63]  L. Kuo,et al.  LDLs impair vasomotor function of the coronary microcirculation: role of superoxide anions. , 1998, Circulation research.

[64]  L. Dobrucki,et al.  Statin-stimulated nitric oxide release from endothelium. , 2001, Medical science monitor : international medical journal of experimental and clinical research.

[65]  M. Lagarde,et al.  Human lymphocytes stimulate prostacyclin synthesis in human umbilical vein endothelial cells. Involvement of endothelial cPLA2 , 2000, Journal of leukocyte biology.

[66]  K. Nakagawa,et al.  The mechanism of thrombin-induced prostacyclin synthesis in human endothelial cells with reference to the gene transcription of prostacyclin-related enzymes and Ca2+ kinetics. , 1999, Journal of pharmacological and toxicological methods.

[67]  A. Tsujikawa,et al.  Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. , 2004, The American journal of pathology.

[68]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[69]  H. Syddall,et al.  Risk of macular degeneration in users of statins: cross sectional study , 2001, BMJ : British Medical Journal.